Allergy Therapeutics plc (LON:AGY) has announced the publication of positive data in the journal Immunotherapy, demonstrating the long-lasting efficacy of Pollinex Quattro grass in patients with grass pollen allergy.
The AIM-listed firm said the observational study, led by Professor Stefan Zielen of the Goethe University, Germany, focused on the long-term efficacy of Pollinex Quattro Grass.
The company, specialising in allergy vaccines, said each of the clinical symptoms (runny nose, sneezing and conjunctivitis) were statistically significantly reduced in treated patients compared with controls without allergen-specific immunotherapy.
Allergy Therapeutics said the study concluded that patients treated with Pollinex Quattro Grass vaccine exhibited significant and long-lasting symptom improvements 3-6 years after cessation of treatment.
Manuel Llobet, CEO at Allergy Therapeutics, said: ”Together with the recently announced positive data from our Phase Grass G205 clinical study, we believe that we have a robust data set for our suite of novel allergy product candidates.”
He added: “We look forward to commencing further studies with the goal of developing a strong allergy portfolio to patients globally, including in the significant US market."